Bone Marker Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients With Advanced Multiple Myeloma.

Trial Profile

Bone Marker Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients With Advanced Multiple Myeloma.

Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Nov 2016

At a glance

  • Drugs Zoledronic acid (Primary)
  • Indications Cancer metastases; Multiple myeloma
  • Focus Biomarker; Therapeutic Use
  • Acronyms Z-MARK
  • Sponsors Novartis
  • Most Recent Events

    • 07 Dec 2015 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
    • 03 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 24 Aug 2011 Planned end date changed from Dec 2011 to Apr 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top